Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Free Cash Flow (2016 - 2025)

Perspective Therapeutics' Free Cash Flow history spans 16 years, with the latest figure at -$16.3 million for Q3 2025.

  • For Q3 2025, Free Cash Flow rose 55.18% year-over-year to -$16.3 million; the TTM value through Sep 2025 reached -$44.8 million, down 13.3%, while the annual FY2024 figure was -$18.4 million, 50.27% up from the prior year.
  • Free Cash Flow for Q3 2025 was -$16.3 million at Perspective Therapeutics, up from -$20.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $13.1 million in Q4 2024 and bottomed at -$36.4 million in Q3 2024.
  • The 5-year median for Free Cash Flow is -$4.4 million (2022), against an average of -$6.8 million.
  • The largest annual shift saw Free Cash Flow surged 437.44% in 2021 before it plummeted 11858.24% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $2.8 million in 2021, then tumbled by 325.41% to -$6.2 million in 2022, then fell by 28.96% to -$8.0 million in 2023, then skyrocketed by 263.15% to $13.1 million in 2024, then plummeted by 224.46% to -$16.3 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Free Cash Flow are -$16.3 million (Q3 2025), -$20.0 million (Q2 2025), and -$21.6 million (Q1 2025).